PDF(Pubmed)
Abstract：
BACKGROUND: Combined large cell neuroendocrine carcinoma (C-LCNEC) has a poor prognosis and there is no consensus about the treatment regimen for both LCNEC and C-LCNEC patients.
METHODS: The patient was a 47-year-old female who received surgical resection. The postoperative histology and staging of the tumor suggested C-LCNEC with adenocarcinoma and squamous cell carcinoma and T2aN0M0 stage IB. Next-generation sequencing test showed KIF5B/RET fusion mutation without EGFR, ALK, RB1, and TP53 alterations. Adjuvant chemotherapy with 4-cycle docetaxel plus carboplatin was given and brain metastasis occurred after 10 months.
CONCLUSIONS: C-LCNEC with adenocarcinoma and squamous cell carcinoma is rare and highly aggressive cancer. Surgical resection and adjuvant chemotherapy with SCLC regimen may improve the disease-free survival and overall survival. The accumulation of similar cases will clarify the profile and management of the disease.
METHODS: The patient was a 47-year-old female who received surgical resection. The postoperative histology and staging of the tumor suggested C-LCNEC with adenocarcinoma and squamous cell carcinoma and T2aN0M0 stage IB. Next-generation sequencing test showed KIF5B/RET fusion mutation without EGFR, ALK, RB1, and TP53 alterations. Adjuvant chemotherapy with 4-cycle docetaxel plus carboplatin was given and brain metastasis occurred after 10 months.
CONCLUSIONS: C-LCNEC with adenocarcinoma and squamous cell carcinoma is rare and highly aggressive cancer. Surgical resection and adjuvant chemotherapy with SCLC regimen may improve the disease-free survival and overall survival. The accumulation of similar cases will clarify the profile and management of the disease.
摘要：
背景：合并大细胞神经内分泌癌（C-LCNEC）的预后较差，对于LCNEC和C-LCNEC患者的治疗方案尚无共识。
方法：患者为一名接受手术切除的47岁女性。术后组织学和分期提示C-LCNEC伴腺癌和鳞状细胞癌，T2aN0M0IB期。下一代测序检测显示KIF5B/RET融合突变无EGFR,ALK,RB1和TP53改变。给予4周期多西他赛联合卡铂辅助化疗，10个月后发生脑转移。
结论：C-LCNEC伴腺癌和鳞状细胞癌是罕见且高度侵袭性的癌症。手术切除和SCLC方案辅助化疗可提高无病生存率和总生存率。类似病例的积累将阐明疾病的概况和管理。
方法：患者为一名接受手术切除的47岁女性。术后组织学和分期提示C-LCNEC伴腺癌和鳞状细胞癌，T2aN0M0IB期。下一代测序检测显示KIF5B/RET融合突变无EGFR,ALK,RB1和TP53改变。给予4周期多西他赛联合卡铂辅助化疗，10个月后发生脑转移。
结论：C-LCNEC伴腺癌和鳞状细胞癌是罕见且高度侵袭性的癌症。手术切除和SCLC方案辅助化疗可提高无病生存率和总生存率。类似病例的积累将阐明疾病的概况和管理。
